Aspirin for the prevention of cognitive decline in the elderly: Rationale and design of a neuro-vascular imaging study (ENVIS-ion)

BMC Neurology

Volumn 12, Issue , 2012, Pages

  Reid, Christopher M ^a   Storey, Elsdon ^a   Wong, Tien Y ^b,c   Woods, Robyn ^a   Tonkin, Andrew ^a   Wang, Jie J ^b,e   Kam, Anthony ^a   Janke, Andrew ^a   Essex, Rowan ^d   Abhayaratna, Walter P ^d   Budge, Marc M ^d  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

AGED; ARTICLE; AUSTRALIA; BRAIN INFARCTION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELDERLY CARE; EXECUTIVE FUNCTION; FOLLOW UP; HUMAN; LONGEVITY; MENTAL FUNCTION; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC DISK; OUTPATIENT CARE; PATIENT ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RETINA BLOOD VESSEL; TREATMENT DURATION; UNITED STATES; WHITE MATTER; AGING; METHODOLOGY; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; AGING; ASPIRIN; AUSTRALIA; BRAIN INFARCTION; COGNITION; COGNITION DISORDERS; DOUBLE-BLIND METHOD; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROPSYCHOLOGICAL TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RETINAL VESSELS; UNITED STATES;

EID: 84856620048     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-12-3     Document Type: Article

References (45)

1. Daviglus ML, Bell CC, Berrettini W, Bowen PE, Connolly ES, Cox NJ, Dunbar-Jacob JM, Granieri EC, Hunt G, McGarry K, et al. National Institutes of Health State-of-the-Science Conference Statement: Preventing Alzheimer's Disease and Cognitive Decline. NIH State-of-the-Science Conference Statement 2010, 27(4):1-30.
2. Van Hooren SAH, Valentijn AM, Bosma H, Ponds RWHM, Van Boxtel MPJ, Jolles J. Cognitive functioning in healthy older adults aged 64-81: A cohort study into the effects of age, sex, and education. Aging, Neuropsychology, and Cognition 2007, 14(1):40-54.
3. Driscoll I, Resnick SM, Troncoso JC, An Y, O'Brien R, Zonderman AB. Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly. Annals of Neurology 2006, 60(6):688-695. 10.1002/ana.21031, 17192929.
4. Hsiung GYR, Donald A, Grand J, Black SE, Bouchard RW, Gauthier SG, Loy-English I, Hogan DB, Kertesz A, Rockwood K, et al. Outcomes of cognitively impaired not demented at 2 years in the Canadian Cohort Study of Cognitive Impairment and Related Dementias. Dementia and Geriatric Cognitive Disorders 2006, 22(5-6):413-420. 10.1159/000095751, 16966831.
5. Piguet O, Grayson DA, Creasey H, Bennett HP, Brooks WS, Waite LM, Broe GA. Vascular risk factors, cognition and dementia incidence over 6 years in the Sydney Older Persons Study. Neuroepidemiology 2003, 22(3):165-171. 10.1159/000069886, 12711848.
6. Ince PG. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001, 357(9251):169-175.
7. Clarke R, Joachim C, Esiri M, Morris J, Bungay H, Molyneux A, Budge M, Frost C, King E, Barnetson L, et al. Leukoaraiosis at presentation and disease progression during follow-up in histologically confirmed cases of dementia. 2000, 903:497-500.
8. Shepherd CE, Piguet O, Broe GA, Creasey H, Waite LM, Brooks WS, Kril JJ. Histocompatibility antigens, aspirin use and cognitive performance in non-demented elderly subjects. Journal of Neuroimmunology 2004, 148(1-2):178-182. 10.1016/j.jneuroim.2003.11.007, 14975599.
9. Kang JH, Cook N, Manson J, Buring JE, Grodstein F. Low dose aspirin and cognitive function in the women's health study cognitive cohort. British Medical Journal 2007, 334(7601):987-990. 10.1136/bmj.39166.597836.BE, 1867896, 17468120.
10. Fujita S, Kawaguchi T, Uehara T, Fukushima K. Progress of leukoaraiosis is inhibited by correction of platelet hyper-aggregability. International Psychogeriatrics 2005, 17(4):689-698. 10.1017/S104161020500164X, 16271159.
11. Antithrombotic Trialists C Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. The Lancet 2009, 373(9678):1849-1860. Antithrombotic Trialists C.
12. Bracco L, Piccini C, Moretti M, Mascalchi M, Sforza A, Nacmias B, Cellini E, Bagnoli S, Sorbi S. Alzheimer's disease: Role of size and location of white matter changes in determining cognitive deficits. Dementia and Geriatric Cognitive Disorders 2005, 20(6):358-366. 10.1159/000088562, 16192726.
13. Sato H, Koretsune Y, Fukunami M, Kodama K, Yamada Y, Fujii K, Kitagawa K, Hori M. Aspirin attenuates the incidence of silent brain lesions in patients with nonvalvular atrial fibrillation. Circulation Journal 2004, 68(5):410-416. 10.1253/circj.68.410, 15118280.
14. Vermeer SE, Den Heijer T, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MMB. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2003, 34(2):392-396. 10.1161/01.STR.0000052631.98405.15, 12574548.
15. Ryan CM, Geckle MO, Orchard TJ. Cognitive efficiency declines over time in adults with Type 1 diabetes: Effects of micro- and macrovascular complications. Diabetologia 2003, 46(7):940-948. 10.1007/s00125-003-1128-2, 12819900.
16. Wong TY. Is retinal photography useful in the measurement of stroke risk?. Lancet Neurology 2004, 3(3):179-183. 10.1016/S1474-4422(04)00682-9, 15029894.
17. Wong T, Mitchell P. The eye in hypertension. Lancet 2007, 369(9559):425-435. 10.1016/S0140-6736(07)60198-6, 17276782.
18. Schneider R, Rademacher M, Wolf S. Lacunar infarcts and white matter attenuation: Ophthalmologic and microcirculatory aspects of the pathophysiology. Stroke 1993, 24(12):1874-1879. 10.1161/01.STR.24.12.1874, 8248970.
19. Cooper LS, Wong TY, Klein R, Sharrett AR, Bryan RN, Hubbard LD, Couper DJ, Heiss G, Sorlie PD. Retinal microvascular abnormalities and MRI-defined subclinical cerebral infarction: The atherosclerosis risk in communities study. Stroke 2006, 37(1):82-86.
20. Ding J, Patton N, Deary IJ, Strachan MWJ, Fowkes FGR, Mitchell RJ, Price JF. Retinal microvascular abnormalities and cognitive dysfunction: A systematic review. British Journal of Ophthalmology 2008, 92(8):1017-1025. 10.1136/bjo.2008.141994, 18614569.
21. Wong TY, Klein R, Sharrett AR, Nieto FJ, Boland LL, Couper DJ, Mosley TH, Klein BEK, Hubbard LD, Szklo M. Retinal microvascular abnormalities and cognitive impairment in middle-aged persons: The Atherosclerosis Risk in Communities Study. Stroke 2002, 33(6):1487-1492. 10.1161/01.STR.0000016789.56668.43, 12052979.
22. Wong TY, Klein R, Couper DJ, Cooper LS, Shahar E, Hubbard LD, Wofford MR, Sharrett AR. Retinal microvascular abnormalities and incident stroke: The Atherosclerosis Risk in Communities Study. Lancet 2001, 358(9288):1134-1140. 10.1016/S0140-6736(01)06253-5, 11597667.
23. Wong TY, Klein R, Sharrett AR, Duncan BB, Couper DJ, Tielsch JM, Klein BEK, Hubbard LD. Retinal arteriolar narrowing and risk of coronary heart disease in men and women: The Atherosclerosis Risk in Communities Study. Journal of the American Medical Association 2002, 287(9):1153-1159. 10.1001/jama.287.9.1153, 11879113.
24. Ikram MK, De Jong FJ, Van Dijk EJ, Prins ND, Hofman A, Breteler MMB, De Jong PTVM. Retinal vessel diameters and cerebral small vessel disease: The Rotterdam Scan Study. Brain 2006, 129(1):182-188.
25. Kwa VIH, Van der Sande JJ, Stam J, Tijmes N, Vrooland JL. Retinal arterial changes correlate with cerebral small-vessel disease. Neurology 2002, 59(10):1536-1540.
26. May GS, Eberlein KA, Furberg CD, Passamani ER, DeMets DL. Secondary prevention after myocardial infarction: A review of long-term trials. Progress in Cardiovascular Diseases 1982, 24(4):331-352. 10.1016/0033-0620(82)90010-X, 6119737.
27. Troche CJ, Tacke J, Hinzpeter B, Danner R, Lauterbach KW. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. European Heart Journal 1998, 19(SUPPL C):C59-C65.
28. Katz S, Akpom CA. A measure of primary sociobiological functions. International Journal of Health Services 1976, 6(3):493-508. 10.2190/UURL-2RYU-WRYD-EY3K, 133997.
29. Teng EL, Chui HC. The Modified Mini-Mental State (MMS) examination. Journal of Clinical Psychiatry 1987, 48(8):314-318.
30. Ruff RM, Light RH, Parker SB, Levin HS. Benton controlled Oral Word Association Test: Reliability and updated norms. Archives of Clinical Neuropsychology 1996, 11(4):329-338.
31. Brandt J, Benedict R. Hopkins verbal learning test - revised. 2001, Inc PAR. Lutz, Fla.
32. Strauss E, Sherman M, Spreen O. A compendium of Neuropsychological Tests. 2006, New York: Oxford University Press, 3.
33. Radloff LS, Teri L. Use of the Center for Epidemiological Studies-Depression Scale with older adults. Clinical Gerontologist 1986, 5(1-2):119-136.
34. Pohjasvaara T, Leskelä M, Vataja R, Kalska H, Ylikoski R, Hietanen M, Leppävuori A, Kaste M, Erkinjuntti T. Post-stroke depression, executive dysfunction and functional outcome. European Journal of Neurology 2002, 9(3):269-275. 10.1046/j.1468-1331.2002.00396.x, 11985635.
35. Stroop JR. Studies of interference in serial verbal reactions. Journal of Experimental Psychology 1935, 18(6):643-662.
36. D'Elia L. Color Trails Test: Professional Manual. 1996, Odessa, FL: Psychological Assessment Resources.
37. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Desmond DW. Research criteria for subcortical vascular dementia in clinical trials. Journal of Neural Transmission, Supplement 2000, (59):23-30.
38. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, Powers WJ, DeCarli C, Merino JG, Kalaria RN, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006, 37(9):2220-2241. 10.1161/01.STR.0000237236.88823.47, 16917086.
39. Evans AC. The NIH MRI study of normal brain development. NeuroImage 2006, 30(1):184-202. 10.1016/j.neuroimage.2005.09.068, 16376577.
40. Hubbard LD, Brothers RJ, King WN, Clegg LX, Klein R, Cooper LS, Sharrett AR, Davis MD, Cai J. Methods for evaluation of retinal microvascular abnormalities associated with hypertension/sclerosis in the Atherosclerosis Risk in Communities Study. Ophthalmology 1999, 106(12):2269-2280. 10.1016/S0161-6420(99)90525-0, 10599656.
41. Knudtson MD, Lee KE, Hubbard LD, Wong TY, Klein R, Klein BEK. Revised formulas for summarizing retinal vessel diameters. Current Eye Research 2003, 27(3):143-149. 10.1076/ceyr.27.3.143.16049, 14562179.
42. Verluis CE, van der Mast RC, van Buchem MA, Bollen ELEM, Blauw GJ, Eekhof JAH, van der Wee NJA, de Craen AJM, Shepherd J, Cobbe SM, et al. Progression of cerebral white matter lesions is not associated with development of depressive symptoms in elderly subjects at risk of cardiovascular disease. The PROSPER Study. International Journal of Geriatric Psychiatry 2006, 21(4):375-381. 10.1002/gps.1477, 16534770.
43. Van Den Heuvel DMJ, Admiraal-Behloul F, Ten Dam VH, Olofsen H, Bollen ELEM, Murray HM, Blauw GJ, Westendorp RGJ, De Craen AJM, Van Buchem MA. Different progression rates for deep white matter hyperintensities in elderly men and women. Neurology 2004, 63(9):1699-1701.
44. Patton N, Aslam T, MacGillivray T, Pattie A, Deary IJ, Dhillon B. Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: A rationale based on homology between cerebral and retinal microvasculatures. Journal of Anatomy 2005, 206(4):319-348. 10.1111/j.1469-7580.2005.00395.x, 1571489, 15817102.
45. Bush TL, Riedel D. Screening for total cholesterol: Do the National Cholesterol Education Program's recommendations detect individuals at high risk of coronary heart disease?. Circulation 1991, 83:1287-1293.